Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome.

Front Oncol

Department of Clinical Haematology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.

Published: April 2022

Despite the development of highly effective, targeted inhibitors of B-cell proliferation and anti-apoptotic pathways in chronic lymphocytic leukemia (CLL), these treatments are not curative, and many patients will develop either intolerance or resistance to these treatments. Transformation of CLL to high-grade lymphoma-the so-called Richter syndrome (RS)-remains a highly chemoimmunotherapy-resistant disease, with the transformation occurring following targeted inhibitors for CLL treatment being particularly adverse. In light of this, cellular therapy in the form of allogenic stem cell transplantation and chimeric antigen receptor T-cell therapy continues to be explored in these entities. We reviewed the current literature assessing these treatment modalities in both high-risk CLL and RS. We also discussed their current limitations and place in treatment algorithms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095984PMC
http://dx.doi.org/10.3389/fonc.2022.888109DOI Listing

Publication Analysis

Top Keywords

cellular therapy
8
chronic lymphocytic
8
lymphocytic leukemia
8
richter syndrome
8
targeted inhibitors
8
therapy high-risk
4
high-risk relapsed/refractory
4
relapsed/refractory chronic
4
leukemia richter
4
syndrome despite
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!